公开(公告)号：US20240254556A1

公开(公告)日：2024-08-01

申请号：US18560569

申请日：2022-05-13

Applicant: GENZYME CORPORATION

Inventor： Darren Phillip BAKER ,  Emanuele DE RINALDIS ,  Richa HANAMSAGAR ,  Evis HAVARI ,  Virginia SAVOVA ,  Srinivas SHANKARA

IPC: C12Q1/6883 ,  C12Q1/6874 ,  G01N33/564

CPC classification number: C12Q1/6883 ,  C12Q1/6874 ,  G01N33/564 ,  C12Q2600/158 ,  G01N2800/046 ,  G01N2800/285 ,  G01N2800/50 ,  G01N2800/52

Abstract: The invention provides methods of assessing the risk of secondary autoimmunity in a patient with a primary autoimmune disease (e.g., MS) following lymphocyte depleting therapy (e.g., anti-CD52 antibody therapy) based on the fraction of a novel cell type termed platelet lineage cells (PLCs) among total cells, and/or the Immature Platelet Fraction (IPF) value, in a biological sample from the patient.